GLP1R and acute kidney injury: A previous study showed that treatment with a GLP-1 receptor agonist or alogliptin, another DPP-4 inhibitor, attenuated cisplatin-induced acute kidney injury, and the knockdown of renal GLP-1 receptor expression in vivo by small interfering RNA reversed the renoprotective effects of alogliptin [20].